Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients

European Journal of Clinical Pharmacology

Volumn 65, Issue 9, 2009, Pages 903-911

  Leger F ^a   Nguyen, L ^a   Puozzo, C ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Actual body weight (ABW); Adjusted ideal body weight (AIBW); Bioequivalence; Haematopoietic stem cell transplantation (HSCT); Pharmacokinetics

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; PHENYTOIN;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOEQUIVALENCE; BODY WEIGHT; CHRONIC MYELOID LEUKEMIA; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; FEMALE; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; SEIZURE; SOLID TUMOR; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BUSULFAN; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING;

EID: 69249205684     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0652-5     Document Type: Article

References (29)

1. JP Gibbs CA Liacouras RN Baldassano JT Slattery 1999 Up-regulation of glutathione S-transferase activity in enterocytes of young children Drug Metab Dispos 27 1466 1469
2. JP Gibbs G Murray L Risler, et al. 1997 Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan Cancer Res 57 5509 5516
3. M Hassan P Ljungman P Bolme, et al. 1994 Busulfan bioavailability Blood 84 2144 2150
4. M Czerwinsky JP Gibbs JT Slattery 1996 Busulfan conjugation by glutathione S-transferases α, μ, and π Drug Metab Dispos 24 1015 1019
5. L Nguyen F Léger S Lennon C Puozzo 2006 Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study Cancer Chemother Pharmacol 57 191 198
6. H Ehrsson M Hassan M Ehrnebo M Beran 1983 Busulfan kinetics Clin Pharmacol Ther 34 86 89
7. M Hassan G Oberg H Ehrsson, et al. 1989 Pharmacokinetic and metabolic studies of high-dose busulphan in adults Eur J Clin Pharmacol 36 525 530
8. LB Grochow RJ Jones RB Brundrett, et al. 1989 Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 25 55 61
9. M Hassan G Oberg AN Bekassi, et al. 1991 Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology Cancer Chemother Pharmacol 28 130 134
10. JP Gibbs T Gooley B Borneau, et al. 1999 The impact of obesity and disease on busulfan oral clearance in adults Blood 93 4436 4440
11. U Schuler S Schroer A Kühnle, et al. 1994 Busulfan pharmacokinetics in bone marrow transplant patient: is drug monitoring warranted? Bone Marrow Transplant 14 759 765
12. Committee for Proprietary Medicinal Products (CPMP) (2001) Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98, London
13. E Diletti D Hauschke W Steinijans 1991 Sample size determination for bioequivalence assessment by means of confidence intervals Int J Clin Pharmacol Ther Toxicol 29 1 8
14. LB Grochow 1993 Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens Semin Oncol 20 4 Suppl 4 18 25
15. JT Slattery JE Sanders CD Buckner, et al. 1995 Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 16 31 42
16. BS Andersson PF Thall T Madden, et al. 2002 Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for IV BuCy2 in chronic myelogenous leukaemia Biol Blood Marrow Transplant 8 477 485
17. JT Slattery RA Clift CD Buckner, et al. 1997 Marrow transplantation for chronic myeloid leukaemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 89 3055 3060
18. B Bostrom K Enockson A Johnson, et al. 2003 Plasma pharmacokinetics of high-dose Oral busulfan in children and adults undergoing bone marrow transplantation Ped Transplant 7 Suppl 3 12 18
19. C Lindley T Shea J McCune, et al. 2004 Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy Anticancer Drugs 15 453 459
20. BS Andersson T Madden HT Tran, et al. 2000 Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study Biol Blood Marrow Transplant 6 548 554
21. BS Andersson A Kashyap V Gian, et al. 2003 Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study Biol Blood Marrow Transplant 8 145 154
22. Puozzo C, Fuller D, Nguyen L et al (2003) A novel dosing to improve safety / efficacy of a IV BU/CY regimen in children (PEDS) undergoing haematopoietic progenitor cell transplantation (HPCT). Proc Am Soc Clin Oncol 22:809 Abstract 3252
23. Santos ES, de Cesare T, Goodman M et al (2004) The efficacy and long-term toxicity of intravenous Busulfan and cyclophosphamide conditioning regimen for stem cell transplantation in advanced lymphoma. Blood 104(11): Abstract 5215
24. Sobocinski KA, Thall PF, Bekele N et al (2004) Matched pairs analysis of IV vs. PO busulfan as a conditioning agent prior to transplantation. Blood 104:(11) Abstract 2308
25. G Vassal M Ré A Gouyette 1988 Gas chromatographic-mass spectrometry assay for busulfan in biological fluids using deuterated internal standard J Chromatogr 428 357
26. Food and Drug Administration (2001) Guidance for industry - statistical approaches to establishing bioequivalence. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CEDER), Washington DC
27. M Hassan G Oberg AN Bekassy, et al. 1991 Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology Cancer Chemother Pharmacol 28 130
28. G Vassal D Challine S Koscielny, et al. 1993 Chronopharmacology of high-dose busulfan in children Cancer Res 53 1534
29. US Schuler M Ehrsam A Schneider, et al. 1998 Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation Bone Marrow Transplant 22 241 244